Celgene
Bristol-Myers to acquire Celgene for $74 billion: Is it time for the M&A biotech boom?
January 08 by Pharma IQBristol-Myers acquisition of Celgene would create a powerful pharma company with leading positions in immune-oncology and the treatment of blood cancers.
NHS England makes Cancer Drug Cut proposals to prevent £70m over-spend
September 08 by Chanice HenryNHS England has reviewed the arrangement of its Cancer Drug Fund and has announced the de-listing of some life-extending cancer treatments. In a recent announcement NHS England noted that the deci...
How can Pharma Distribution Make an Impact in the Boardroom?
May 19 by Helen WinsorFrank Binder, Director of International Logistics and Supply Chain at Celgene, joins Helen Winsor at Pharma IQ, to discuss how pharmaceutical distribution can add more value to business. Firstly, he...
Celgene's Expansion into Asia
December 17 by Andrea CharlesDr. Frank Binder, Director, International Logistics & Supply Chain at Celgene, joins Andrea Charles from Pharma IQ, to discuss the key considerations for selecting business models across As...